Added to YB: 2025-09-11
Pitch date: 2025-09-11
MDXH [bullish]
MDxHealth SA
-88.7%
current return
Author Info
Company Info
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.
Market Cap
$23.4M
Pitch Price
$3.84
Price Target
N/A
Dividend
N/A
EV/EBITDA
-9.71
P/E
-0.70
EV/Sales
0.78
Sector
Biotechnology
Category
growth
Diagnostics company with 20%+ topline growth hits inflection point
MDXH: Prostate cancer diagnostics one-stop shop. 17 straight quarters 20%+ growth, revenue doubled since 2022 w/o adding reps, just turned adj EBITDA+. Trades 2x EV/Rev vs Veracyte 4x (historically 6x). $174M cap, $285M EV. ExoDx acquisition adds $20M rev, EBITDA accretive. Risks: $42M net debt, $54M GPS + $15M ExoDx earn-outs, NCCN/reimbursement changes. Catalysts: US re-listing, ExoDx close, 2026 guidance, operating leverage, multiple re-rating.
Read full article (11 min)